FDA Slams Paradigm Insulin Pump by Medtronic, Inc. Over Quality Issues

Published: Oct 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FDA regulators handed Medtronic a warning letter over issues associated with its Paradigm-branded insulin infusion pumps. This comes on top of a Class I recall this past summer over a faulty part in the infusion pump system. On September 19th, regulators alerted the company to violations found during an inspection of its production facility in Northridge, CA.

Help employers find you! Check out all the jobs and post your resume.

Back to news